)
Natco Pharma Limited said on Monday it signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the US drugmaker's chronic hepatitis C medicines.
Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a statement.
Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
